Therapeutic Area | MeSH |
---|---|
musculoskeletal diseases | D009140 |
nutritional and metabolic diseases | D009750 |
Brand Name | Status | Last Update |
---|---|---|
forteo | New Drug Application | 2024-11-13 |
teriparatide | ANDA | 2024-10-14 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Teriparatide, Forteo, Lilly | |||
7517334 | 2025-03-25 | DP |
Code | Description |
---|---|
J3110 | Injection, teriparatide, 10 mcg |
Drug common name | Teriparatide |
INN | teriparatide |
Description | TERIPARATIDE |
Classification | Protein |
Drug class | peptides: parathyroid hormone related peptide |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C |
PDB | — |
CAS-ID | 52232-67-4 |
RxCUI | — |
ChEMBL ID | CHEMBL525610 |
ChEBI ID | — |
PubChem CID | 16132393 |
DrugBank | DB06285 |
UNII ID | 10T9CSU89I (ChemIDplus, GSRS) |